

# EXHIBIT 1

You are here : [Home Page](#) > [About us](#)

## Welcome to sanofi-aventis in the United States



[About us](#) | [Products](#) | [Health Matters](#) | [Press](#) | [Investors](#) | [Careers](#) | [R&D](#) | [Social Responsibility](#)

[US Web Sites](#) [Contact us](#) [Sitemap](#)



[Sanofi-aventis worldwide](#)

[Sanofi-aventis in the US](#)

[Facility Locations](#)

[Packaging Services](#)

[Corporate Compliance  
Program](#)

[Our Values](#)

### Sanofi-aventis in the U.S. Company Profile

Sanofi-aventis is one of the world's largest pharmaceutical companies. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines.

Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

In 2006, sanofi-aventis generated sales of approximately € 28.4 billion, invested more than € 4.4 billion in research and development, and employed approximately 100,000 people in its core business. Corporate headquarters are in Paris, France.

Sanofi-aventis conducts business in the U.S. through its headquarters in Bridgewater, New Jersey.

#### Sanofi-aventis worldwide

Sanofi-aventis is one of the world's largest pharmaceutical companies.

[► Read more](#)

#### Letter from our U.S. Chairman

Timothy Rothwell  
Chairman, Group Pharmaceutical Activities  
sanofi-aventis U.S.

[► Read more](#)



### Corporate Information

Get more information about  
sanofi-aventis group

[► Read more](#)



November 07, 2007

Retrospective Analysis Finds  
that Initiation of Insulin  
Glargine in Patients with  
Type 2 Diabetes was  
Associated with a Lower  
Incidence Rate of Myocardial  
Infarction as Compared with  
NPH Insulin

[► Read more](#)